Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout

Meltzer M, Pizzi LT, Jutkowitz E

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details
Meltzer M, Pizzi LT, Jutkowitz E. Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout. Evidence-Based Medicine 2012; 17(4): 105-108

PubMedID
22345034

DOI
10.1136/ebmed-2011-100065

Original Paper URL
http://ebm.bmj.com/content/17/4/105.short

Indexing Status
Subject indexing assigned by NLM

MeSH
Allopurinol /economics /therapeutic use; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Making; Decision Trees; Febuxostat; Gout /drug therapy /economics; Gout Suppressants /economics /therapeutic use; Humans; Thiazoles /economics /therapeutic use

AccessionNumber
22012033015

Date bibliographic record published
04/01/2013